UCB CEO to Chair IMI Board for a Second Term
Complete the form below to unlock access to ALL audio articles.
UCB and IMI have announced that CEO Roch Doliveux has again been appointed Chair of the Governing Board of the Innovative Medicines Initiative (IMI), a public-private partnership between the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
UCB has been a member of IMI since its initiation in 2006 with Roch Doliveux joining the IMI Governing Board in May 2010, and Chairing the IMI Governing Board from 2012 to 2013.
IMI currently supports 46 projects with a combined budget of around €1.6 billion. IMI projects are tackling some of the biggest challenges in medicines research, with the goal speeding up the development of, and patient access to, better and safer medicines.
In addition, IMI supports a number of education & training projects. IMI has proved highly successful and a proposal to extend the initiative is now under discussion in the European Parliament and the EU Member States.
Roch Doliveux, CEO of UCB and Vice President of the European Federation of Pharmaceutical Association (EFPIA) says “Never has science given us so many opportunities to innovate and provide better health to citizens around the world. Yet science is now so complex that no one can harness its potential on its own. IMI is the biggest public-private partnership of its kind, and a role model for open innovation and knowledge sharing between the industry and academia. It is also without a doubt a key instrument to increase the well-being of patients across Europe.”
Michel Goldman, Executive Director of IMI said: “Roch Doliveux has long been a strong supporter of IMI, and his dedication and vision, and those of his colleagues on the Governing Board, have helped to make IMI the strong, successful organization it is today. I am confident that his leadership skills, combined with his focus on the needs of patients, will ensure IMI goes from strength to strength as it moves into the next phase of its existence.”
UCB is a significant contributor to the Innovative Medicines Initiative. UCB is participating in 21 of the consortia within IMI, leading 3 projects with academic partners: BTCURE, PRECISEADS and AETIONOMY.
